Risk Factors Associated With Recurrence and Death in Patients With Tall Cell Papillary Thyroid Cancer

Author:

Wu Shannon S.1,Joshi Nikhil2,Sharrett Jonathan3,Rao Sanjay4,Shah Akeesha5,Scharpf Joseph6,Burkey Brian7,Lamarre Eric D.6,Prendes Brandon6,Siperstein Allan8,Shin Joyce9,Berber Eren9,Jin Judy9,Krishnamurthi Vikram9,Nasr Christian9,Hong Li10,Buchberger David S.3,Woody Neil3,Koyfman Shlomo A.3,Geiger Jessica L.11

Affiliation:

1. Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio

2. Department of Radiation Oncology, Rush University Medical Center, Chicago, Illinois

3. Department of Radiation Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, Ohio

4. Case Western Reserve University School of Medicine, Cleveland, Ohio

5. Department of Anatomic Pathology, Cleveland Clinic, Cleveland, Ohio

6. Department of Otolaryngology, Cleveland Clinic, Cleveland, Ohio

7. Department of Otolaryngology, Cleveland Clinic, Vero Beach, Florida

8. Department of Endocrine Surgery, Cleveland Clinic, Cleveland, Ohio

9. Department of Endocrinology, Cleveland Clinic, Cleveland, Ohio

10. Department of Statistics, Cleveland Clinic, Cleveland, Ohio

11. Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, Ohio

Abstract

ImportanceTall cell morphology (TCM) is a rare and aggressive variant of papillary thyroid carcinoma (PTC) that has been associated with poor outcomes; however, the risk factors for worse survival are not well characterized.ObjectiveTo identify prognostic factors associated with cancer recurrence and death in patients with PTC-TCM.Design, Setting, and ParticipantsAll patients treated for PTC-TCM at a single tertiary-level academic health care institution from January 1, 1997, through July 31, 2018, were included. Tall cell variant (TCV) was defined as PTC with TCM of 30% or more; and tall cell features (TCF) was defined as PTC with TCM of less than 30%. Patients with other coexisting histologic findings and/or nonsurgical management were excluded. Clinicopathologic features associated with worse outcomes were identified using Kaplan-Meier and Cox proportional-hazards model. Data were analyzed from March 1, 2018, to August 15, 2018.Main Outcomes and MeasuresLocoregional recurrence-free survival (LRRFS), distant recurrence-free survival (DRFS), and overall survival (OS) after surgery.ResultsA total of 365 patients (median [range] age, 51.8 [15.9-91.6] years; 242 [66.3%] female) with PTC-TCM (TCV, 32%; TCF, 68%) were evaluable. Total thyroidectomy was performed in 336 (92%) patients; 19 (5.2%) received radiotherapy; and 15 (4.1%) received radioactive iodine. Clinical features were pT3 or T4, 65%; node-positive, 53%; and positive surgical margins, 24%. LRRFS at 1-, 3-, 5-, and 10-year was 95%, 87%, 82%, and 73%, respectively. On multivariable analysis, male sex and age were not independent predictors of inferior 5-year LRRFS, whereas positive surgical margins (HR, 3.5; 95% CI, 2.0-6.3), positive lymph nodes (HR, 2.8; 95% CI, 1.4-5.8), and primary tumor size of 3 cm or more (HR, 3.3; 95% CI, 1.4-7.8) were strongly associated with worse LRRFS. Age 55 years or older (HR, 3.2; 95% CI, 1.5-7.0), male sex (HR 4.5; 95% CI, 2.1-10.0), positive surgical margins (HR, 2.7; 95% CI, 1.2-6.0), nodal positivity (HR, 3.1; 95% CI, 1.3-7.7), tumor diameter of 1.5 cm or more (HR, 20.6; 95% CI, 2.8-152.1), and TCV vs TCF (HR, 3.1; 95% CI, 1.5-6.7) were associated with worse DRFS. Male sex (HR, 3.1; 95% 1.4-6.8) and tumor diameter of 1.5 cm or more (HR, 2.8; 95% CI, 1.0-7.4) were associated with worse OS. A findings-based nomogram was constructed to predict 10-year LRRFS (C index, 0.8).Conclusions and RelevanceThis retrospective cohort study found that in patients with PTC-TCM, positive surgical margins, node positive disease, and tumor size of 3 cm or more were risk factors for worse LRRFS. Intensified locoregional therapy, including adjuvant radiation, may be considered for treating these patients.

Publisher

American Medical Association (AMA)

Subject

Otorhinolaryngology,Surgery

Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3